The year 2018 witnessed a landmark decision on the cannabis front. Various states joined hands in legalizing the medicinal use of cannabis. This decision was based on a number of positive research that supported cannabis to be a potential drug that can effectively treat various diseases. Today cannabis doctors across these states and countries prescribe cannabis-based treatments to ease various ailments and discomfort associated with them.
CBD may “act as an adjunct to enhance treatment efficacy” in glioblastoma multiforme, which is “the most common and aggressive form of primary malignant brain tumor in adults”, according to a study published by the journal Translational Oncology.
“Glioblastoma multiforme (GBM) is the most common and aggressive form of primary malignant brain tumor in adults, with poor prognosis”, states the study’s abstract. “Extracellular vesicles (EVs) are key-mediators for cellular communication through transfer of proteins and genetic material. Cancers, such as GBM, use EV release for drug-efflux, pro-oncogenic signaling, invasion and immunosuppression; thus the modulation of EV release and cargo is of considerable clinical relevance.”
As EV-inhibitors have been shown to increase sensitivity of cancer cells to chemotherapy, “and we recently showed that cannabidiol (CBD) is such an EV-modulator”, researchers “investigated whether CBD affects EV profile in GBM cells in the presence and absence of temozolomide (TMZ).” Compared to controls, “CBD-treated cells released EVs containing lower levels of pro-oncogenic miR21 and increased levels of anti-oncogenic miR126; these effects were greater than with TMZ alone. In addition, prohibitin (PHB), a multifunctional protein with mitochondrial protective properties and chemoresistant functions, was reduced in GBM cells following 1 h CBD treatment.”
A new study published by the Brazilian Journal of Psychiatry “confirm the anxiolytic-like [anti-anxiety] properties of CBD”.
“Cannabidiol (CBD), one of the non-psychotomimetic compounds of Cannabis sativa, causes anxiolytic-like effects in animals, with typical bell-shaped dose-response curves”, states the study’s abstract. “No study, however, has investigated whether increasing doses of this drug would also cause similar curves in humans. The objective of this study was to compare the acute effects of different doses of CBD and placebo in healthy volunteers performing a simulated public speaking test (SPST), a well-tested anxiety-inducing method.”
A total of 57 healthy male subjects were allocated to receive oral CBD at doses of 150 mg, 300 mg, 600 mg or placebo in a double-blind procedure. “During the SPST, subjective ratings on the Visual Analogue Mood Scale (VAMS) and physiological measures (systolic and diastolic blood pressure, heart rate) were obtained at six different time points.”
CBD-rich extracts which contain at least a small amounts of other cannabinoids “present a better therapeutic profile” than CBD alone, according to a new study published by the journal Frontiers in Neurology.
The study, titled Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy, states that the improved benefits of high-CBD cannabis extracts over pure CBD “is likely due to synergistic effects of CBD with other phytocompounds (aka Entourage effect)”.
According to the study’s abstract. “This meta-analysis paper describes the analysis of observational clinical studies on the treatment of refractory epilepsy with cannabidiol (CBD)-based products. Beyond attempting to establish the safety and efficacy of such products, we also investigated if there is enough evidence to assume any difference in efficacy between CBD-rich extracts compared to purified CBD products.”
In a new study published by the journal Neurology, 80% of children with autism saw improvements in their condition after being administered cannabidiol (CBD).
For the study, 60 children with an average age of 12 were given cannabis oil containing 20% CBD and 1% THC, for a period of seven months.
After the seven-month period, children filled out a questionnaire asking if they noticed any changes in their condition. Parents were asked if they noticed any changes in their child’s condition, and were asked about any changes in their child’s anxiety levels and communication abilities.
In an odd situation, CBD comany Phoenix Tears sent out a press release recently announcing that by the end of the year 4,500 7-Eleven stores will be selling their product, only to be quickly refuted by 7-Eleven who says that isn’t true.
On Tuesday Phoenix Tears sent out a press release stating that hundreds of 7-Eleven stores will “immediately” begin selling their products, with the number rising to 4,500 by the end of the year. However, Stephanie Shaw, director of communications for 7-Eleven, told HuffPost that the purported deal was false.
“We have made no agreement or partnership with this company and do not know why they said that,” Shaw said.
According to a new study published by the journal Addiction, a single dose of cannabidiol (CBD) reduces the salience and pleasantness of cigarette cues, compared with a placebo.
“Cannabidiol (CBD), a non-intoxicating cannabinoid, may be a promising novel smoking cessation treatment due to its anxiolytic properties, minimal side-effects and research showing it may modify drug cue salience”, begins the abstract of this “Randomized, double-blind crossover study with a fixed satiated session followed by two overnight abstinent sessions.”
For the study, researchers “used an experimental medicine approach with dependent cigarette smokers to investigate if (1) overnight nicotine abstinence, compared with satiety, will produce greater attentional bias (AB), higher pleasantness ratings of cigarette-related stimuli and increased craving and withdrawal; (2) CBD in comparison to placebo, would attenuate AB, pleasantness of cigarette-related stimuli, craving and withdrawal and not produce any side-effects.”
CBD (cannabidiol) and CBD-rich extracts may provide a potential treatment option for endometrial cancer, according to a new study published by the Journal of Physiology and Biochemistry, and published online by the U.S. National Institute of Health.
“Among a variety of phytocannabinoids, Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most promising therapeutic compounds”, begins the study’s abstract. “Besides the well-known palliative effects in cancer patients, cannabinoids have been shown to inhibit in vitro growth of tumor cells. Likewise, the major endocannabinoids (eCBs), anandamide (AEA) and 2-arachidonoylglycerol (2-AG), induce tumor cell death.”
The purpose of the present study “was to characterize cannabinoid elements and evaluate the effect of cannabinoids in endometrial cancer cell viability.” Endometrial cancer is a variety of cancer that begins in the lining of the uterus.
Washington’s House Appropriations Committee has approved a measure that would allow marijuana outlets to “use cannabidiol products (CBD products) obtained from sources other than state licensed producer/processors”.
House Bill 2334, filed by Representative David Sawyer, “Authorizes licensed marijuana producers and processors to use cannabidiol products (CBD products) obtained from sources other than state licensed producer/processors, provided such products are laboratory tested, approved by the Liquor and Cannabis Board (LCB), and meet other specified requirements.”
The measure “Requires that all CBD products used by licensed producers and processors meet legal standards for product safety and purity”, creates a legal definition of “CBD Product”, and “Provides the LCB with rule making authority regarding the use of CBD products by licensed marijuana producers and processors.”
Indiana’s House of Representatives has voted unanimously to approve legislation that would legalize cannabidiol (CBD) oil.
cbd2Indiana’s House approved House Bill 1214 with a unanimous 93 to 0 vote. The measure now moves to the state’s Senate, where a similar measure was recently passed by its initial committee. If passed by the Senate, the proposal would be sent to Governor Eric Holcomb for final consideration.
House Bill 1214 “Specifies that the definition of “industrial hemp” includes the resins of the Cannabis sativa plant. Defines “CBD oil” as a product that contains: (1) not more than 0.3% THC; (2) at least 5% cannabidiol; and (3) no other controlled substances. Legalizes CBD oil”, and “Repeals superseded provisions relating to cannabidiol registration.”